Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 5/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.34 |
| ▸ | CDK9 | P50750 | 4/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | QDPR | P09417 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5821626 | 0.76 | CCNT1 (0.42) | SIGMAR1CCNT1CDK9CACNA1GKCNH2 | |
| SCHEMBL5821411 | 0.73 | CCNT1 (0.45) | CCNT1CDK9CACNA1GKCNH2PARP1 | |
| SCHEMBL5066879 | 0.72 | DRD2 (0.45) | HTR7SIGMAR1PPARGPPARAKDM4E | |
| SCHEMBL4563258 | 0.71 | SIGMAR1 (0.46) | HTR7SIGMAR1PPARGPPARAKDM4E | |
| SCHEMBL5824183 | 0.70 | CCNT1 (0.39) | SIGMAR1CCNT1CDK9KDM4EMAPT | |
| SCHEMBL5950685 | 0.68 | KDM4E (0.39) | SIGMAR1CCNT1CDK9KDM4EMAPT | |
| SCHEMBL5067573 | 0.66 | PARP1 (0.41) | CCNT1CDK9PPARGPPARACACNA1G | |
| SCHEMBL5822824 | 0.65 | CCNT1 (0.45) | SIGMAR1CCNT1CDK9PPARGPPARA | |
| SCHEMBL5950590 | 0.64 | CDK9 (0.38) | SIGMAR1CCNT1CDK9KDM4EMAPT | |
| SCHEMBL5806705 | 0.62 | MAPT (0.44) | KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235037-A1 | Heterocyclic inhibitors of protein arginine methyl transferases | BRISTOL-MYERS SQUIBB COMPANY | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235037-A1 | Heterocyclic inhibitors of protein arginine methyl transferases | PRMT1, PRMT3, PRMT8 | HTR7 4465/4885SIGMAR1 4801/4885CCNT1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.